Cytoreductive surgery after recurrent epithelial ovarian cancer and at other timepoints

Table 1 Risk model for secondary cytoreductive surgery in patients with recurrent ovarian cancer based on the international collaborative cohort

Impact factors	Scoring
	0	0.8	1.5	1.8	2.4	3
FIGO stage	I/II	III/IV
Residual disease at 1st surgery	0		> 0
Progression-free interval (mo)	> 16				< 16
ECOG performance status	0-1				2-3
Ca 125 at recurrence (U/mL)	< 105			> 105
Ascites at recurrence	Absent					Present

Low risk ≤ 4.7, complete resection feasible from 53% to 83%; high risk ≥ 4.7, complete resection feasible from 20% to 42%. FIGO: International Federation of Gynecology and Obstetrics; ECOG: Eastern Cooperative Oncology Group.